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Abstract
Background: Better methods to predict prognosis can play a supplementary role in administering individualized
treatment for breast cancer patients. Altered expressions of PTHrP and TGF-β have been observed in various types
of human cancers. The objective of the current study was to evaluate the association of PTHrP and TGF-β level with
the clinicopathological features of the breast cancer patients.
Methods: Immunohistochemistry was used to examine PTHrP and TGF-β protein expression in 497 cases of early
breast cancer, and Kaplan-Meier method and COX’s Proportional Hazard Model were applied to the prognostic
value of PTHrP and TGF-β expression.
Results: Both over-expressed TGF-β and PTHrP were correlated with the tumor in larger size, higher proportion of
axillary lymph node metastasis and later clinical stage. Additionally, the tumors with a high TGF-β level developed
poor differentiation, and only TGF-β expression was associated with disease-free survival (DFS) of the breast cancer
patients. Followed up for a median of 48 months, it was found that only the patients with negative TGF-β
expression had longer DFS (P < 0.05, log-rank test). Nevertheless, those with higher PTHrP expression tended
to show a higher rate of bone metastasis (67.6 % vs. 45.8 %, P = 0.019). In ER negative subgroup, those who
developed PTHrP positive expression presented poor prognosis (P < 0.05, log-rank test). The patients with both
positive TGF-β and PTHrP expression were significantly associated with the high risk of metastases. As indicated by
Cox’s regression analysis, TGF-β expression and the high proportion of axillary lymph node metastasis served as
significant independent predictors for breast cancer recurrence.
Conclusions: TGF-β and PTHrP were confirmed to be involved in regulating the malignant progression in breast
cancer, and PTHrP expression, to be associated with bone metastasis as a potential prognostic marker in ER negative
breast cancer.
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Background
Breast cancer, remaining the most global common malig-
nant tumor in women, is yearly diagnosed in more than
one million cases [1]. Although the continuously improved
understanding of the tumor pathology and significant
advancements in diagnostic techniques have allowed more
cases to be detected at an earlier stage, the overall 5-year
survival rate remains low for breast cancer patients, primar-
ily because of the high rate of recurrence and metastasis
[2]. Tumor cells have been well recognized to show a
distinctive attribute for metastasis to specific organs; the
1889 Stephen Paget’s original “seed and soil” hypothesis
was reported that the organ-preference patterns of tumor
metastasis were the product of interactions between meta-
static tumor cells (the seed) and their organ microenviron-
ment (the soil) [3]. Breast cancer is known to have a strong
predilection for bone metastasis and only 20 % of the
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patients are still five-year alive after confirmation for the
serious complication of breast cancer [4, 5].
Parathyroid hormone-related protein (PTHrP), iso-
lated from the tumor tissues of Malignancy-associated
hypercalcemia (MAH) patients, was reported to be
credited for its ability to mimic parathyroid hormone
(PTH) [6, 7]. During embryonic period, PTHrP plays
an important role in normal mammary gland, tooth
and bone development and differentiation [8–11].
PTHrP was reported to be expressed in a wide variety
of fetal and adult tissues, as well as in many malignan-
cies [6, 12]. PTHrP expression was reported to be
present in many tumor types even in the absence of
hypercalcemia, and related with tumor progression
such as colon cancer, non-small cell lung cancer, mye-
loma and prostatic cancer [13–18]. In bone metastasis,
PTHrP plays a key role in the osteoclastic bone re-
sorption by stimulating receptor activator for nuclear
factor-κ B ligand (RANKL) expression [19, 20]. A re-
cent study in PyMT-MMTV breast cancer mouse
model reported that PTHrP expression level was cor-
related with breast cancer metastasis and tumor cell
survival [21].
TGF-β has been recognized to be a multi-functional
growth factor involved in regulation of such processes as
development, wound healing, fibrosis, carcinogenesis,
angiogenesis, and immunity [22–24], and also to play a crit-
ical and double role in the progression of cancer [25, 26].
In the development of breast cancer, tumor cells obtain
resistance to TGF-β-mediated growth arrest, it has been
reported that TGF-β pathway retains the ability to promote
the processes that support tumor progression such as
tumor cell epithelial-to-mesenchymal transition, invasion,
dissemination, and immune evasion [27–29]. Additionally,
bone metastasis lesions-derived TGF-β can serve a critical
mediator of breast carcinoma-mediated progression of
osteolytic bone lesions, and the effector of this response is
PTHrP. PTHrP and TGF-β can promote mutual expression
and form a vicious circle [4, 19]. However, the relative
quantitative expressions of TGF-β and PTHrP have not
been fully explored in primary tumor tissues.
In the current study, we aimed to assess whether PTHrP
and TGF-β can be dysregulated in the breast cancer
tissues by analyzing clinicopathologic features and their
potential value in the prognosis of breast cancer patients.
The results showed that expression level of PTHrP and
TGF-β in the tissues was associated with the clinicopatho-
logic features, which could serve as an independent prog-
nostic factor for the patients after surgery.
Methods
Specimen cohorts
From January 2006-December 2009, specimens were ob-
tained from the female patients with operable primary
breast cancer, who underwent treatment at the Depart-
ment of Breast Surgery of Zhongshan Hospital affiliated
to Fudan University and Yangpu Hospital affiliated to
Tongji University School of Medicine. From a total num-
ber of the consecutive patients, we randomly selected 497
paraffin blocks of tumor tissues of the invasive patients,
341 cases from Yangpu Hospital and 156 cases from
Zhongshan Hospital for the current study (random num-
bers table) after excluding those on neoadjuvant chemo-
therapy or those with positive margins on histopathology.
All the patients underwent breast cancer surgery and stan-
dardized adjuvant therapies. Meanwhile, 40 specimens of
benign breast tumor tissues were collected as controls.
The selected patients were classified into three groups
according to cTNM staging system of American Joint
Committee on Cancer (AJCC), 195, 210 and 92 on stage I,
II and III, respectively.
All the patients were followed up via interviews on the
phone and outpatient visits every month, which began
from the first postoperative day to December 2012, and
ended up with 389 patients with a median of 48 months
(range of 2 to 85 months), 108 patients lost during the
process. After surgery, 116 patients suffered from local
recurrence or distant metastasis. The local or regional
recurrence was confirmed by histology and the distant
metastasis was detected by biopsy or imaging tech-
niques. By the end of this period, 26 patients had died,
21 of breast cancer, and 273 patients had developed no
recurrence. The relapse-free interval (RFI) of the patients
was calculated. This study was approved by medical ethics
committee of Zhongshan Hospital affiliated to Fudan
University (No.2010-78) and Yangpu Hospital affiliated to
Tongji University (No.LL-2010-2-DOB-003) with the pa-
tient informed consents. Conforming to the principles
outlined in WMA Declaration of Helsinki-Ethical Princi-
ples for Medical Research Involving Human Subjects,
tissue samples were collected from Zhongshan Hospital
and Yangpu Hospital at surgery, immediately fixed in
formalin, and then dehydrated and embedded in paraffin.
Immunohistochemical staining
Tissue microarrays (TMAs) were constructed containing
the tumor tissues of 537 patients, 40 of whom showed
benign tissues. Two core biopsies with a diameter of
0.8 mm of each case were transferred from the donor
blocks to the predefined positions on the recipient paraffin
blocks. The consecutive sections measured 4 μm in thick-
ness were placed on the 3-aminopropyltriethoxysilane-
coated slides.
The primary antibodies for the immunohistochemical
analyses were as follows: PTHrP antibody monoclonal,
(diluted 1:2000, ABGENAT), TGF-β rabbit polyclonal anti-
body (diluted 1:5000, SANTA CRUZ). The analyses were
carried out using a two-step protocol: Upon microwave
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antigen retrieval, the tissues were incubated with primary
antibodies overnight at 4 °C, followed by a 30-min in-
cubation with HRP-conjugated goat anti-rabbit/mouse
IgG (horseradish peroxidase-conjugated anti mouse/
rabbit immunoglobin, EnVision Detection Kit A solu-
tion, Gene Tech, Hk) at room temperature, and then a
3-min incubation with diaminobenzidine, before coun-
terstained with hematoxylin and examined under
OLYMPUS BX51 microscope. Sections of human pla-
centa were stained as PTHrP and TGF-β positive con-
trol. The negative control slides without the primary
antibodies were included in all assays. All immuno-
stained slides were reviewed and judged as positive/nega-
tive staining by two histopathologists independently in a
blinded manner. In most cases, the results were identical
from two pathologists, and the discrepancies were re-
solved by re-examination and consensus.
Statistical analysis
The correlation of TGF-β or PTHrP expression evalu-
ated by IHC staining and the relevant clinicopathologic
features were analyzed using Pearson’s χ2 correlation
test. Disease-free survival (DFS) was defined as the
period from the operative date to the first recurrence
(local or distant) or death of breast cancer without a re-
corded relapse. Cumulative survival time of each group
was calculated by the Kaplan-Meier method and ana-
lyzed by the log-rank test. In the multivariate analysis, a
COX’s Proportional Hazard Model was employed to es-
timate whether a factor was a significant independent
prognostic factor of survival. All statistical tests were
two-sided, and P values less than 0.05 were considered
as statistically significant. The statistical analyses were
performed using SPSS 22.0 software (SPSS Inc.).
Results
Immunohistochemical tissue staining
An analysis was made of a tissue obtainment containing
497 breast cancer patients and 40 benign breast tumor
patients, all females, with the median age of 56.7 in the
former (ranging from 26 to 95), and with the median
age 43.2 in the latter (from 22 to 72). The staining of
TGF-β and PTHrP was mainly observed on the cyto-
plasm of cells in the breast tumor tissues (Fig. 1a, c),
and most of the stroma areas were negative staining.
Almost half of the breast tumors exhibited positive levels
of TGF-β and PTHrP expression, 55.1 % in 274 cases,
54.5 % in 271 cases, respectively. Both TGF-β and
PTHrP positive staining were rarely detected in the
benign breast tissues, 10 % in 4 cases and 17.5 % in 7
cases, respectively.
Correlation of TGF-β expression and clinicopathologic
features
All breast cancer cases were separated into two groups
as TGF-β positive and TGF-β negative based on the
TGF-β staining degree of the tumor sections. Compared
with those with TGF-β negative staining, the patients
with TGF-β positive had poor differentiation in histology
and larger tumor size, and most in the positive group
showed a higher proportion of axillary lymph node me-
tastasis and later clinical stages. In the two groups, how-
ever, no significant difference was observed on patients’
age, skin involvement, pathological type, and expression
of estrogen receptor and HER-2 (Table 1).
Correlation of PTHrP expression and clinicopathologic
features
The histopathological parameters were further compared
in both PTHrP positive and negative group. Analogously,
Fig. 1 Photographs of TGF-β and PTHrP expression in breast cancer tissues by immunohistochemical staining. a.b Representative images of
TGF-β positive (a) or TGF-β negative (b) cases with immunostaining (magnification × 200); c.d Representative images of PTHrP positive (c) or
PTHrP negative (d) cases with immunostaining (magnification × 200)
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the results showed that in the positive group, larger tumor
size, higher proportion of axillary lymph node metastasis
and later clinical stages were observed, and that the two
groups displayed no significant distinction in patients’ age,
skin involvement, degrees of pathological differentiation,
pathologic type of cancer, level of estrogen receptor (ER)
and HER-2 (Table 2).
The previously reported results suggested that the high
levels of TGF-β and PTHrP were significantly correlated
with the features of more advanced breast cancer such
as larger tumor size, higher proportion of axillary lymph
node metastasis and later clinical stages. In the current
study, however, such features showed little association
with these two oncoprotein levels. Remarkably, only
breast cancer patients with high level of TGF-β pre-
sented poor pathological differentiation.
TGF-β/PTHrP expression and survival
As indicated by the findings of the 389 follow-ups, the
recurrence rate was approximately 32.1 % and 27.1 % in
212 and 177 cases in PTHrP positive and negative
group, respectively. Those who displayed higher PTHrP
expressions tended to have a higher bone metastasis rate
(67.6 % vs. 45.8 %, P = 0.019) (Table 3), but the data of
Kaplan-Meier lifetime analysis showed no significant
difference of the cumulative DFS in the positive and
negative group, respectively (Fig. 2a).
To examine further the relationship between TGF-β
level and breast cancer patients’ survival, all cases were
divided into two groups based on TGF-β level; conse-
quently, there were 225 cases of TGF-β positive. As
shown by Fig. 3, when compared with high TGF-β con-
trols, the group without detectable TGF-β expression
was significantly associated with longer DFS among 164
patients (P < 0.05, log-rank test) (Fig. 2b).
When all cases were further divided into two subgroups
by the expression of estrogen receptor staining signal,
Kaplan-Meier lifetime analysis demonstrated that those
who expressed lower PTHrP in ER negative subgroup had
favorable prognosis (P < 0.05, log-rank test) (Fig. 3a). In
ER positive group, nevertheless, no statistically significant
differences were observed in the prognosis of those who
had positive or negative PTHrP expression (3b). Contrast-
ive analysis of the DFS in ER and PTHrP groups proved
that those with negative ER and positive PTHrP expres-
sion developed the worst prognosis.
As indicated by DFS curves constructed for the com-
parison of four different groups based on PTHrP and
TGF-β survival results, the prognosis of those with posi-
tive TGF-β and PTHrP expression was obviously worse
than that of those with negative TGF-β, independently
of PTHrP changes (Fig. 3c). These results clearly indicated
a statistically significant correlation between PTHrP/TGF-β
up-regulation and poorer survival outcome.
Based on the results from the multivariate COX’s Pro-
portional Hazard Model to evaluate the clinical values of
TGF-β/PTHrP in prognosis, it was found that the abnor-
mal expression of TGF-β was an independent prognostic
factor for DFS in breast cancer patients (HR = 0.469,
95.0 % CI 0.301 to 0.729; P < 0.05). The results also re-
vealed that proportion of axillary lymph node metasta-
sis and histologic grade were related to the prognosis
of breast cancer. More importantly, the high propor-
tion of axillary lymph node metastasis was the most







≤55 156 (56.9 %) 111 (49.8 %) 2.534 0.111
>55 118 (43.1 %) 112 (50.2 %)
Tumor size
≤2 cm 137 (50.0 %) 141 (63.2 %) 8.729 0.003
>2 cm 137 (50.0 %) 82 (36.8 %)
Skin involvementa
No 229 (83.6 %) 190 (85.2 %) 0.245 0.620
Yes 45 (16.4 %) 33 (14.8 %)
LN metastasis
No 154 (57.5 %) 148 (67.9 %) 5.556 0.018
Yes 114 (42.5 %) 70 (32.1 %)
Unknown 6 5
Histologic grade
≤II 182 (67.7 %) 169 (78.2 %) 6.710 0.01
>II 87 (32.3 %) 47 (21.8 %)
Unknown 5 7
Clinical stage
I 91 (33.2 %) 104 (46.6 %) 9.329 0.009
II 128 (46.7 %) 82 (36.8 %)
III 55 (20.1 %) 37 (16.6 %)
ER
(−) 75 (28.7 %) 59 (27.6 %) 0.079 0.779
(+) 186 (71.3 %) 155 (72.4 %)
Unknown 13 9
HER-2
(−) 94 (38.7 %) 83 (41.7 %) 0.417 0.518
(+) 149 (61.3 %) 116 (58.3 %)
Unknown 31 24
Tumor type
IDCb 234 (85.4 %) 189 (84.8 %) 0.041 0.840
Non-IDCc 40 (14.6 %) 34 (15.2 %)
askin involvement: edema, redness, nodularity, or ulceration
bIDC, invasive ductal carcinoma
cNon-IDC: invasive lobular carcinoma, mucinous or colloid carcinoma, medullary
carcinoma, metaplastic carcinoma
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effective unfavorable prognostic factor in DFS (HR =
2.054, 95.0 % CI 1.398 to 3.019; P < 0.05). However,
the multivariate analysis indicated that PTHrP was not
an independent prognostic factor in breast cancer
(HR = 1.022, 95.0 % CI 0.684 to 1.527; P > 0.05)
(Table 4).
Discussion
Breast cancer originates in mammary epithelial cells,
with a clear tendency to lymph node and blood metasta-
sis; however, PTHrP is expressed in the normal epithelial
cells, but its expression rises in breast cancer, becoming
associated with multiple metastatic lesions. Recently,
Ghoussaini et al. combined several datasets, encompass-
ing 70,000 patients and 68,000 controls and identified
rs10771399, a 300 kb linkage disequilibrium block that
contains only one gene, PTHrP, one of the candidate
genes connecting with the mammary gland development
and breast cancer bone metastasis [30]. Li J et al. used
the MMTV-Cre transgene to target the PTHrP gene in
mammary epithelial cells in PyMT-MMTV GEM model,
finding out that it could prolong tumor latency, inhibit
tumor growth and repress metastases. Tumor growth
inhibition was reported to be correlated with reduced
proliferation and increased apoptosis [21]. But according
to the previously reported clinical researches, the rela-
tion between PTHrP and tumor progression remains
controversial. As reported by Linforth R, PTHrP was
expressed in 68 % of surgically excised early breast can-
cers, when compared with 100 % bone metastases; and
co-expression of both PTHrP and receptor predicted the
worst clinical outcome [31]. However, another investiga-
tion of 3 year-postoperative following-ups found no
difference in PTHrP expression of the primary tumor
amongst the metastasis-free group, distant-recurrence
group and other preoperative distant disease group [32].
The results reported by Surowiak showed that the pa-
tients with high expression of PTHrP manifested longer
survival than those with lower PTHrP expression [33].
Additionally, a retrospective clinical study of breast
tumors collected at surgery suggested better outcome
Table 2 Clinicopathologic features and PTHrP expression
PTHrP positive PTHrP negative χ2 P
valueNo. (%) No. (%)
Age
≤55 146 (53.9 %) 121 (53.5 %) 0.006 0.941
>55 125 (46.1 %) 105 (46.5 %)
Tumor size
≤2 cm 133 (49.1 %) 145 (64.2 %) 11.372 0.001
>2 cm 138 (50.9 %) 81 (35.8 %)
Skin involvementa
No 223 (82.3 %) 196 (86.7 %) 1.834 0.176
Yes 48 (17.7 %) 30 (13.3 %)
LN metastasis
No 154 (57.7 %) 148 (67.6 %) 5.014 0.025
Yes 113 (42.3 %) 71 (32.4 %)
Unknown 4 7
Histologic grade
≤II 187 (70.8 %) 165 (74.7 %) 0.885 0.347
>II 77 (29.2 %) 56 (25.3 %)
Unknown 7 5
Clinical stage
I 95 (35.1 %) 100 (44.2 %) 6.937 0.031
II 116 (42.8 %) 94 (41.6 %)
III 60 (22.1 %) 32 (14.2 %)
ER
(−) 78 (29.2 %) 56 (26.9 %) 0.303 0.582
(+) 189 (70.8 %) 152 (73.1 %)
Unknown 4 18
HER-2
(−) 98 (40.3 %) 79 (39.7 %) 0.018 0.893
(+) 145 (59.7 %) 120 (60.3 %)
Unknown 28 27
Tumor type
IDCb 231 (85.2 %) 192 (85.0 %) 0.008 0.929
Non-IDCc 40 (14.8 %) 34 (15.0 %)
TGF-β
(−) 116 (42.8 %) 107 (47.3 %) 1.027 0.311
(+) 155 (57.2 %) 119 (52.7 %)
askin involvement: edema, redness, nodularity, or ulceration
bIDC, invasive ductal carcinoma
cNon-IDC: invasive lobular carcinoma, mucinous or colloid carcinoma,
medullary carcinoma, metaplastic carcinoma
Table 3 Recurrence or metastasis in PTHrP positive/negative
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and survival in the patients whose primary tumor
over-expressed PTHrP [34]. The current study was an
assessment of the inconsistent results derived from
the previously reported clinical researches.
The important role of TGF-β in breast cancer develop-
ment has been extensively investigated. Recent studies
have revealed that TGF-β activates its receptors through
ligand binding, thus resulting in a further activation of
Smad family proteins through phosphorylation, and that
nuclear-localizated Smad proteins regulates the tran-
scription of target genes [35]. TGF-β, a potent mediator
of growth inhibition, is capable of inducing apoptosis in
a variety of tumors at early stage. In the advanced tu-
mors, however, TGF-β activation seems to enhance
breast tumor growth and invasion. As a critical negative
regulator of the immune system, TGF-β inhibits T cells
and antigen present cell by preventing cell-mediated
tumor clearance in tumor progression [36, 37]. TGF-β
functions as a potent inducer of breast cancer angiogen-
esis by increasing the expression of vascular endothelial
growth factor (VEGF) expression [38, 39]. It has been
suggested that TGF-β can cause epithelial-mesenchymal
transition (EMT) via Smad pathway and its downstream
effect genes, and also up-regulate plasminogen activator,
MMP-2 and MMP-9, which degrade extracellular
matrix, allowing for subsequent migration of breast can-
cer cells [40–42]. As a possible trigger of breast cancer
metastasis, additionally, TGF-β which regulates PTHrP
is simultaneously stimulated by PTHrP in bone metasta-
sis [43, 44]. Therefore, the approach we developed in the
current study could be a co-detection of the progression
and prognosis based on these gene expressions in breast
cancer tissues.
In the current study, we further investigated the
correlation between PTHrP/TGF-β expression and clini-
copathologic features of breast cancer. We found that
positive expression of PTHrP/TGF-β was linked to lar-
ger tumor size, higher proportion of axillary lymph node
metastasis and later clinical stages. The cancer biological
functions of PTHrP were reported as followings: PTHrP
can promote primary tumor proliferation by activing
PI3K-Akt, AKR1C3 pathway and affect cell cycle pro-
gression by up-regulating Cyclin D2 and Cyclin A2 pro-
tein levels [17, 45–48]; PTHrP can play an autocrine
neoplastic role in evading apoptosis by decreasing the
levels of Beclin1 and LC3-II or controlling the Bcl-2 and
Caspase family [45, 49, 50]; PTHrP accelerates the adhe-
sion, invasion and metastasis of tumor cells to the bone
[51, 52]; and local increased PTHrP secreted by the
breast cancer metastatic sites stimulating osteoblasts to
express RANKL and inhibit osteoprotegerin (OPG) se-
cretion, PTHrP has been shown to play a key role in the
osteolytic resorption of bone metastasis by activating
osteoclast division and growth [53]. PTHrP expression
has been shown to be under the control of numerous
growth and angiogenic factors such as TGF-β, VEGF,
epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF), and meanwhile it stimulates the
expression of these factors in various cell types and be-
haves as an angiogenic factor in endothelial cells [54].
Fig. 2 a. Kaplan–Meier analyses of the effect PTHrP expression on DFS (P = 0.307, log-rank test); b. Kaplan-Meier analyses of the effect TGF-β
expression on DFS (P = 0.001, log-rank test)
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Combined these protein functions with our research
data, we consider both TGF-β and PTHrP as oncogenes
in breast cancer.
It followed that either PTHrP-positive or TGF-β-
positive breast cancer patients indicated a high risk of
metastasis. Bone, followed by the lung and liver, is one
of the most preferential metastatic target sites for breast
cancer [2]. It has been well recognized that breast cancer
cells spread to distant target organs with their own in-
herent character. Our research suggested that the higher
PTHrP expression the patients tended to have, the
higher bone metastasis rate would be (67.6 % vs. 45.8 %,
P = 0.019). Furthermore, the results of the cross analysis
between different groups showed that the prognosis of
the patients with both positive TGF-β and PTHrP ex-
pression was apparently worse than all the others. Ac-
cording to the Stanley Paget “seed and soil” hypothesis,
tumor cells as “seed” invading bone provide additional
growth factors that activate the bone microenvironment
as “soil,” which in turn produces growth factors that feed
Fig. 3 a. Kaplan-Meier analyses of the effect PTHrP expression in ER negative subgroup on DFS (P=0.027, log-rank test) b. Kaplan-Meier analyses of the
effect PTHrP expression in ER positive subgroup on DFS (P= 0.521, log-rank test) c. Kaplan-Meier analyses of the effect PTHrP and TGF-β expression on DFS
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the tumor cells, creating a vicious cycle of destructive
mutual cooperation [55]. Combined with our current
results, the breast cancer cells which expressed both
TGF-β and PTHrP can be the competent seed that has
the capacity to metastasize to bone. As indicated by the
survival analysis, though no significant difference was
observed in the cumulative DFS of 212 cases with
PTHrP expression and 177 cases with PTHrP negative,
the findings were consistent with those previously re-
ported. In ER negative subgroup, however, those who
expressed positive PTHrP expression presented poor
prognosis, the findings consistent with the results found
in genetically engineered PyMT-MMTV GEM model
which is not representative of ER positive breast cancer
[56]. Usually, ER positive breast cancer accounts for 60
to 70 % of all breast cancers. In our study, we can find
out that the case number and overall DFS of ER positive
subgroup was superior to ER negative subgroup. We
suppose that this is the reason why there was no signifi-
cant difference of the cumulative DFS in the PTHrP
positive and negative group.
Metastasis and recurrence of breast cancer postopera-
tively is probably the major reason of treatment failure
or even death. Further studies on the prognostic factors
of recurrence and metastasis are essential to breast
cancer treatment. In the current study, Cox regression
analysis was applied to determining significant prognos-
tic factors, the results of which showed that TGF-β
expression, LN metastasis and histologic grade can be
the significant prognostic factors. The patients with LN
metastasis were found to be more likely to relapse, the
hazard ratio of DFS is 2.054 (P < 0.01), indicating that
such patients may have about 2 times more risk of
breast cancer relapse; and the hazard ratio of DFS for
TGF-β is 0.469 (P < 0.01), indicating that those with
negative TGF-β might reduce the relapse risk by about
53.1 %. However, PTHrP expression was neither a new
independent prognostic factor nor a single therapeutic
target in breast cancer (HR = 1.022; 95.0 % CI 0.684 to
1.527; P > 0.05). Although it was related to the cancer
development process, PTHrP expression was even of
some survival advantage in the subgroup of the pa-
tients with ER positive breast cancer. A recent experi-
ment suggested that curcuminoids inhibited TGF-β-
induced PTHrP by decreasing phospho-Smad2/3 and
Ets-1 protein levels, thus reducing osteolytic bone de-
struction [57]. In conclusion, TGF-β and PTHrP medi-
ated double-targeted therapy can be well considered
as a novel treatment in breast cancer.
Tumor occurrence and development can be consid-
ered as the accumulation of gene mutations and epigen-
etic modifications. The predominant consequence of this
accumulation is the activation of proto-oncogenes or si-
lencing of tumor-suppressor genes [58]. Consistent with
previous reports that PTHrP can promote the occur-
rence or development of malignant tumors through vari-
ous mechanisms, our results suggested the advanced
extent of breast cancer was correlated with TGF-β and
PTHrP co-expression. More importantly, the patients
with both positive TGF-β and PTHrP expression were
significantly associated with poorest DFS, and the pa-
tients with positive PTHrP expression had worse cumu-
lative survival in ER negative breast cancer. These
results together indicated that TGF-β and PTHrP co-
expression could act as proto-oncogenes in the develop-
ment of breast cancer and that double-targeted therapy
could be considered as a novel therapy for breast cancer.
Conclusions
As verified by the current study, co-expression of TGF-β
and PTHrP can be associated with breast cancer pro-
gression, recurrence and poor postoperative survival
outcomes. PTHrP expression in breast tumors is rele-
vant to bone metastasis. PTHrP expression can act as a
potential prognostic tool in ER negative breast cancer.
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